Literature DB >> 17211430

Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease.

K C Yoon1, I Y Jeong, S K Im, Y G Park, H J Kim, J Choi.   

Abstract

This study was performed to investigate the therapeutic effect of umbilical cord serum eyedrops on dry eye associated with graft-versus-host disease (GVHD). Twenty-four eyes of 12 patients with severe dry eye syndrome associated with GVHD were treated with 20% umbilical cord serum eyedrops. Symptom scoring, corneal sensitivity test, tear film break up time (BUT), Schirmer test, tear clearance rate (TCR), and corneal fluorescein staining were performed before and 2 and 6 months after treatment. Six months after treatment, significant improvement was observed in symptom score (from 3.83+/-0.38 to 0.83+/-0.57, P<0.01), corneal sensitivity (from 52.08+/-6.06 mm to 57.50+/-3.00 mm, P<0.01), tear film BUT (from 2.50+/-0.91 s to 5.71+/-1.04 s, P<0.01), and keratoepitheliopathy score (from 7.42+/-2.02 to 1.29+/-0.46, P<0.01). There was no siginificant change in Schirmer test and TCR results. No significant complications associated with the use of the eyedrops were observed. Umbilical cord serum eyedrops are safe and may be an effective way to treat severe dry eye associated with GVHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211430     DOI: 10.1038/sj.bmt.1705566

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels.

Authors:  Piera Versura; Marina Buzzi; Giuseppe Giannaccare; Marco Grillini; Adriana Terzi; Pasqualepaolo Pagliaro; Emilio C Campos
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 2.  Regenerative Therapy Using Umbilical Cord Serum.

Authors:  Nagarajan Maharajan; Gwang-Won Cho; Ji Hyun Choi; Chul Ho Jang
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease.

Authors:  Kyung-Sun Na; Man Soo Kim
Journal:  J Ocul Pharmacol Ther       Date:  2012-06-25       Impact factor: 2.671

4.  Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects.

Authors:  Elif Erdem; Meltem Yagmur; Inan Harbiyeli; Hande Taylan-Sekeroglu; Reha Ersoz
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

5.  Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops.

Authors:  Piera Versura; Marina Buzzi; Giuseppe Giannaccare; Adriana Terzi; Michela Fresina; Claudio Velati; Emilio C Campos
Journal:  Blood Transfus       Date:  2015-07-09       Impact factor: 3.443

Review 6.  Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations.

Authors:  Nariman Nassiri; Medi Eslani; Nekoo Panahi; Shiva Mehravaran; Alireza Ziaei; Ali R Djalilian
Journal:  J Ophthalmic Vis Res       Date:  2013-10

Review 7.  Dry eye: an inflammatory ocular disease.

Authors:  Michelle Hessen; Esen Karamursel Akpek
Journal:  J Ophthalmic Vis Res       Date:  2014-04

Review 8.  Use of umbilical cord serum in ophthalmology.

Authors:  Kyung Chul Yoon
Journal:  Chonnam Med J       Date:  2014-12-17

Review 9.  Application of Novel Drugs for Corneal Cell Regeneration.

Authors:  Sang Beom Han; Yu-Chi Liu; Karim Mohamed-Noriega; Jodhbir S Mehta
Journal:  J Ophthalmol       Date:  2018-05-02       Impact factor: 1.909

Review 10.  Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease.

Authors:  Yoko Ogawa; Yutaka Kawakami; Kazuo Tsubota
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.